



Praha 16. dubna 2021

Č. j.: MZDR 14455/2021-2/OLZP



MZDRX01FIQEK

ROZHODNUTÍ

Ministerstvo zdravotnictví (dále jen „Ministerstvo“) jako orgán příslušný k rozhodnutí podle ustanovení § 12 odst. 1 písm. h) zákona č. 22/1997 Sb., o technických požadavcích na výrobky a o změně a doplnění některých zákonů, ve znění pozdějších předpisů ve spojení s § 4 odst. 8 nařízení vlády č. 56/2015 Sb., o technických požadavcích na diagnostické zdravotnické prostředky in vitro (dále jen „nařízení vlády“), na základě žádosti společnosti

Locus magnus s.r.o.

se sídlem Karlova 150/42, Staré Město, 110 00 Praha 1, IČO: 043 75 092

(dále jen „žadatel“)

rozhodlo v souladu s ustanovením § 67 a násl. zákona č. 500/2004 Sb., správní řád, ve znění pozdějších předpisů (dále jen „správní řád“) tak, že

povoluje

žadateli uvést na trh a do provozu diagnostický zdravotnický prostředek in vitro **Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva)**, jehož výrobcem je HANGZHOU REALY TECH CO., LTD., se sídlem 4th Floor, #12 Building, Eastern Medicine Town, Xiasha Economic & Technology Development, 10018 Hangzhou, Zhejiang, P.R. China, pro použití laickou osobou

a stanovuje

po dobu platnosti tohoto rozhodnutí žadateli následující povinnosti k zajištění ochrany veřejného zdraví:

- zajistit, aby konečný laický uživatel testu byl informován, že toto povolení se nevztahuje na variantu testu, která využívá nazofaryngeálního odběru vzorku
- informovat odběratele o povinnosti v rámci testování zajistit při pozitivě antigenního testu provedení laickou osobou bezprostřední informování poskytovatele zdravotních služeb za účelem provedení konfirmačního testu,
- v případě zájmu odběratele zajistit školení určené osoby,
- hlásit Státnímu ústavu pro kontrolu léčiv každou nepříznivou událost, ke které během používání výrobku dojde.
- vydat vlastní prohlášení o shodě s Nařízením vlády č. 56/2015 Sb., před uvedením předmětného výrobku na trh

Toto rozhodnutí nabývá účinnosti dnem nabytí právní moci, nejdříve však dne 1. 5. 2021.

Odůvodnění:

I.

Dne 2.4.2021 požádal žadatel o udělení výjimky podle § 4 odst. 8 nařízení pro diagnostický zdravotnický prostředek in vitro určený k sebetestování na onemocnění COVID-19 uvedený ve výroku tohoto rozhodnutí pro účely zavedení celoplošného testování v České republice, jakožto diagnostického zdravotnického prostředku in vitro, pro který nebyl proveden postup podle § 4 odst. 1 až 4 nařízení a jehož použití je v zájmu ochrany zdraví. Žádost zdůvodňuje potřebou pravidelně testovat populaci za účelem včasného odhalení výskytu nových případů onemocnění COVID-19 ještě před jejich rozšířením v kolektivu.

K žádosti přiložil následující dokumentaci:

- a) Prohlášení o shodě vydané originálním (původním) výrobcem
- b) Návod k použití v českém jazyce
- c) Fotodokumentace
- d) Hodnocení funkční způsobilosti
- e) Draft prohlášení o shodě s Nařízením vlády č. 56/2015 Sb., vypracovaný žadatelem jako novým výrobcem
- f) Formulář MZ

II.

Ministerstvo posoudilo předmětný diagnostický zdravotnický prostředek in vitro na základě žadatelem předložených informací jako dostatečně funkčně způsobilý a pro uživatele bezpečný.

Ministerstvo se ztotožňuje s potřebou pravidelně testovat veřejnost rychlými antigenními testy za účelem včasného odhalení výskytu nových případů onemocnění COVID-19 ještě před jejich rozšířením v kolektivech, což při absenci antigenních testů určených pro sebetestování na celém trhu EU není možné řešit jinak, než s použitím vhodných antigenních testů určených pro profesionální použití, jež budou k tomuto účelu použity za účelem odhalení pozitivních osob ve společnosti. Povolení se vztahuje pouze na neinvazivní způsoby odběru vzorku.

Za účelem podpory opatření k ochraně veřejného zdraví je žadateli uložena povinnost informovat odběratele o povinnosti při zjištění pozitivitě antigenního testu provedeného laickou osobou kontaktovat vzdáleným přístupem (telefonicky, e-mailem apod.) závodního lékaře (poskytovatele pracovně – lékařských služeb) nebo registrujícího praktického lékaře, který rozhodne o provedení konfirmačního testu a zajistí komunikaci v rámci systému ISIN. Za účelem minimalizace rizika chyb v provedení odběru a interpretaci výsledků testů je žadateli uložena povinnost v případě zájmu odběratele zajistit proškolení osoby určené odběratelem.

S ohledem na potřebu dalšího vyhodnocování z hlediska bezpečnosti a funkční způsobilosti testů je výjimka z procesu posouzení shody udělena do 30. 6. 2021.

S ohledem na výše uvedené rozhodlo Ministerstvo tak, jak je uvedeno ve výroku tohoto rozhodnutí.



Declaration of Conformity



in accordance with Directive 98/79/EC

Manufacturer:

Name: HANGZHOU REALY TECH CO., LTD.

Address: 4th Floor, #12 Building, Eastern Medicine Town, Xiasha Economic & Technology Development, 310018 Hangzhou, Zhejiang, P. R. China

Product/s	Catalogue number
Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva)	K590516D

Category: Other Devices (All devices except Annex II and self-testing devices)

Conformity assessment route: Annex III, except Point 6, of Directive

Applicable Standards: EN ISO 13485: 2016; EN ISO 15223-1:2016; EN ISO 14971: 2012; EN ISO 13612:2002; EN ISO 17511:2003; EN ISO 18113-1:2011; EN ISO 18113-2:2011, EN ISO 23640:2015.

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint Luxus Lebenswelt GmbH, located at Kochstr.1,47877, Willich, Germany to act as our European Authorised Representative as defined in the aforementioned Directive.

Hangzhou 2020.12.15

(Place and date of issue)



(Signature and position)

Signed for and on behalf of the manufacturer

Allgemeine Anzeigepflicht nach §§ 25 und 30 Abs. 2 MPG **General Obligation to Notify pursuant to §§ 25 and 30 (2) Medical Devices Act, MPG**

Formblatt für In-vitro-Diagnostika / Form for In Vitro Diagnostic Medical Devices

Zuständige Behörde / Competent authority			
Code DE/CA20			
Bezeichnung / Name Bezirksregierung Düsseldorf, Dezernat 24			
Staat / State Deutschland		Land / Federal state Nordrhein-Westfalen	
Ort / City Düsseldorf		Postleitzahl / Postal code 40474	
Straße, Haus-Nr. / Street, house no. Cecilienallee 2			
Telefon / Phone +49-211-4750		Telefax / Fax +49-211-4752671	
E-Mail / E-mail dez24.mpg@brd.nrw.de			

Anzeige / Notification	
Registriertdatum bei der zuständigen Behörde Registration date at competent authority 20.01.2021	Registriernummer / Registration number DE/CA20/01-IVD-Luxuslebenswelt-02/21
Typ der Anzeige / Notification type ☐ Erstanzeige / Initial notification ☐ Änderungsanzeige / Notification of change ☐ Widerrufsanzeige / Notification of withdrawal	
Frühere Registriernummer bei Änderungs- und Widerrufsanzeige Previous registration number if notification has been changed or withdrawn	
Anzeigender nach § 25 MPG / Reporter pursuant to § 25 Medical Devices Act, MPG ☐ Hersteller / Manufacturer ☐ Bevollmächtigter / Authorised Representative ☐ Einführer / Importer ☐ Verantwortlicher für das Zusammensetzen von Systemen oder Behandlungseinheiten nach § 10 Abs. 1 und 2 MPG \ Assembler of systems or procedure packs pursuant to § 10 (1) and (2) Medical Devices Act, MPG ☐ Betrieb oder Einrichtung (aufbereiten) nach § 25 Abs. 1 MPG i. V. m. § 4 Abs. 2 MPBetreibV Institution (processing) pursuant to § 25 (1) Medical Devices Act, MPG in connection with § 4 (2) MPBetreibV ☐ Betrieb oder Einrichtung (sterilisieren) nach § 25 Abs. 2 i. V. m. § 10 Abs. 3 MPG Institution (sterilizing) pursuant to § 25 (2) in connection with § 10 (3) Medical Devices Act, MPG	

Anzeigender / Reporting organisation (person)			
	Code DE/0000047791		
	Bezeichnung / Name Luxus Lebenswelt GmbH		
	Staat / State Deutschland		Land / Federal state Nordrhein-Westfalen
	Ort / City Willich		Postleitzahl / Postal code 47877
	Straße, Haus-Nr. / Street, house no. Kochstr. 1		
	Telefon / Phone 0049-1715605732		Telefax / Fax
	E-Mail / E-mail info.m@luxuslw.de		

Hersteller / Manufacturer			
	Bezeichnung / Name Hangzhou Realy Tech Co.,Ltd.		
	Staat / State CN		
	Ort / City Hangzhou		Postleitzahl / Postal code 310018
	Straße, Haus-Nr. / Street, house no. 4th Floor,#12 Building,Eastern Medicine Town, Xiasha Economic&Technology Development		
	Telefon / Phone 0086-571-56050793		Telefax / Fax 0086-571-56050794
	E-Mail / E-mail ryy@realytech.com		

Sicherheitsbeauftragter für Medizinprodukte nach § 30 Abs. 2 MPG 9) Safety officer for medical devices pursuant to § 30 (2) Medical Devices Act, MPG			
	Bezeichnung / Name Lin Sun		
	Staat / State Deutschland		Land / Federal state Nordrhein-Westfalen
	Ort / City Willich		Postleitzahl / Postal code 47877
	Straße, Haus-Nr. / Street, house no. Kochstr. 1		
	Telefon / Phone 0049-1715605732		Telefax / Fax
	E-Mail / E-mail info.m@luxuslw.de		

Vertreter / Deputy (optional)			
	Bezeichnung / Name		
	Telefon / Phone		Telefax / Fax
	E-Mail / E-mail		
	☐ S Erstanzeige / Initial notification ☐ £ Änderungsanzeige / Notification of change		

In-vitro-Diagnostikum / In vitro diagnostic medical device			
	Klassifizierung / Classification ☐ £ Produkt der Liste A, Anhang II / Device of List A, Annex II ☐ £ Produkt der Liste B, Anhang II / Device of List B, Annex II ☐ £ Produkt zur Eigenanwendung / Device for self-testing ☐ S Sonstiges Produkt / Other device (all devices except Annex II and self-testing devices)		
	App (Software auf mobilen Endgeräten)		☐ £ ja / yes ☐ S nein / no
	Anzeige nach § 25 Abs. 3 Nummer 3 MPG Notification pursuant to § 25 (3) number 3 Medical Devices Act, MPG ☐ £ "Neues In-vitro-Diagnostikum / New in vitro diagnostic medical device"		
	Handelsname des Produktes / Trade name of the device Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva)		
	Produktbezeichnung / Name of device Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva)		
	Angabe der benutzten Nomenklatur / Nomenclature used ☐ S EDMS-Klassifikation / EDMS Classification ☐ £ GMDN		
	Nomenklaturcode / Nomenclature code 15-70-90-90-00		
	Nomenklaturbezeichnung / Nomenclature term OTHER OTHER VIROLOGY RAPID TESTS		
	Kurzbeschreibung / Short description In Deutsch / In German Das neuartige Coronavirus (SARS-Cov-2) -Antigen-Schnelltestgerät (Speichel) ist ein In-vitro-Diagnosteset zum qualitativen Nachweis neuartiger Coronavirus-Antigene im menschlichen Speichel unter Verwendung der schnellen immunochromatographischen Methode. Die Identifizierung basiert auf den monoklonalen Antikörpern, die für das neue Coronavirus-Antigen spezifisch sind. Es wird Informationen für klinische Ärzte bereitstellen, um korrekte Medikamente zu verschreiben.		
	In English / In English The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronavirus antigen. It will provide information for clinical doctors to prescribe correct medications.		

Zusätzliche Angaben im Falle der In-vitro-Diagnostika gemäß Anhang II und der In-vitro-Diagnostika zur Eigenanwendung / Additional information for Annex II and self-testing in vitro diagnostic medical devices	
	Nummer(n) der Bescheinigung(en) / Certificate number(s)
	£ In Übereinstimmung mit den Gemeinsamen Technischen Spezifikationen (für Produkte gem. Anhang II, Liste A) In conformity with Common Technical Specifications (for Annex II List A devices)
	Ergebnisse der Leistungsbewertung Outcome of performance evaluation

Ich versichere, dass die Angaben nach bestem Wissen und Gewissen gemacht wurden.
 I affirm that the information given above is correct to the best of my knowledge.

Ort City Willich 	Datum Date 2020-12-14
Name Lin Sun 	

Unterschrift
Signature

Bearbeitungsvermerke / Processing notes Nur von der zuständigen Behörde auszufüllen / To be filled in only by the competent authority	
Bearbeiter / Person responsible Frau Nadine Schlingmeier	Telefon / Phone 0211-475-3853

Clinical Validation report of Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)



Product name: Novel Coronavirus (SARS-Cov-2) Antigen Rapid
Test device (saliva)

Package Specification: 25 tests/kit

Manufacturer: Hangzhou Realy Tech Co., Ltd

I. Clinical validation time

This clinical evaluation was conducted from October 2020 to November,2020.

II. Background information for clinical evaluation

Since December 2019, world has successively discovered multiple cases of patients with new-type coronavirus pneumonia. With the spread of the epidemic, China and abroad have also been found. As an acute respiratory infectious disease, the disease has been included in the Class B infectious diseases stipulated in the Law of the People's Republic of China on the Prevention and Control of Infectious Diseases, and is managed as a Class A infectious disease. Based on the current epidemiological investigation, the incubation period is 1-14 days, mostly 3-7 days.

The main manifestations are fever, dry cough, and fatigue. A few patients have symptoms such as nasal congestion, runny nose, sore throat, myalgia and diarrhea. Severe patients usually have dyspnea and / or hypoxemia one week after the onset of symptoms, and severe patients can quickly progress to acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis, coagulation dysfunction and multiple organ Functional failure, etc. It is worth noting that in the course of severe and critically ill patients, there may be moderate to low fever, even without obvious fever.

Mild patients showed only low fever, mild fatigue, and no pneumonia. Judging from the current cases, most patients have a good prognosis, and a few patients are critically ill. The elderly and those with chronic underlying disease have a better prognosis. Symptoms in children are relatively mild.

The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) developed by our company can help diagnose whether patients are infected with the Novel Coronavirus. It has further enriched the detection methods of Novel Coronavirus, expanded the supply of detection reagents, and fully served the needs of epidemic prevention and control.

III. Test purposes

The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) produced by Hangzhou Realy Technology Co., Ltd. was used to verify the feasibility of clinical evaluation and the reliability of test results for Chinese subjects.

The purpose of research of the clinical test is to calculate the consistency percentage of negative/positive and the total consistency percentage and Kappa coefficient by statistically analyzing test results through comparative experimental research.

IV. Test design

1. Test plan selection and reasons

In vitro diagnostic reagents for testing and reference reagents were used to conduct comparative research tests on clinically suspected Novel Coronavirus saliva samples, and it was proved that the in vitro diagnostic reagents used in the test can achieve the expected assistance in infection of the Novel Coronavirus.

2. Sample volume required

The total number of clinical trials of this product is not less than 100 cases. The samples is classified into the positive group and the negative group as per the test results of the reference product. Meanwhile, the (unfrozen) nasopharyngeal swab samples shall be tested via the RT-PCR from the same patient at same time , then the saliva sample test results of the product tested and the

nasopharyngeal swab sample RT-PCR test results shall be compared, with statistical analysis being made.

3. Sample inclusion/exclusion certification.

The positive group and negative group in this experiment are applicable to the following inclusion/exclusion criteria.

Positive group inclusion:

PCR Test is positive;
symptoms are clinically positive;

Negative inclusion:

PCR test is negative;

Sample collection, processing

It is applicable to the diagnosis of the Novel coronavirus from the samples of saliva. Use freshly collected samples for optimal test performance. Inadequate sample collection or improper sample handling may yield a false-negative result.

Sample collection procedure: The oral fluid specimen should be collected using the saliva collector provided with the kit. Follow the detailed Directions for Use refer to product IFU. No other collection cup should be used with this assay. Oral fluid collected at any time of the day may be used. **NOTE: Do not place anything in the mouth including food, drink, gum, tobacco, water and mouthwash products for at least 10 minutes prior to collection of oral fluid specimen.**

Specimen preparation:

Take out a sample extraction tube, remove the aluminum foil, Insert the sponge of sample collector with the saliva sample into the tube and twist close the whole cap of sample collector.

4. In vitro diagnostic reagents and reference products for testing

5.1 Test in vitro diagnostic reagents

Name: Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)

Specification: 25 tests/kit

LOT: 202010001

Expiry: October, 2022 (Tentative)

Storage Conditions: Store in a dry place at 2-30°C, protected from light. After opening the inner package, the test card will become invalid due to moisture absorption. Please use it within 1 hour.

Source: Hangzhou Realy Tech Co., Ltd

5.2 Reference products

Name: Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing)

Manufacturer: Sansure Biotech Inc.

Storage Conditions: Store in a dry place at 2-8°C, protected from light.

V. Experiment method

1. Open the package with the saliva collector, then remove the saliva collector from the sealed plastic bag.
2. Pre-process the saliva samples according to the instructions of the The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva), and label the samples randomly.

- 2.1 Insert the sponge of saliva collector into the mouth, actively swab the inside of the mouth and tongue to collect oral fluid for approximately 10 second until the sponge becomes soft and fully saturated, The sponge will be free from hard spots when fully saturated.
- 2.2 . Take out a sample extraction tube, remove the aluminum foil. Remove the collector from the mouth and put the saturated oral fluid collector into the extraction tube.
- 2.3 Screw the cap into the extraction tube tightly so that saliva is squeezed out of the sponge into the extraction tube.
- 2.4 Gently shake the extraction tube vertically for about 5 seconds to allow saliva mix well with extraction buffer. Take out the saliva collector and discard it.
3. The operation steps of the in vitro diagnostic reagents for the test are as follows. For details, please refer to the product instruction manual:
 - 3.1 Remove the test device from the sealed foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed immediately after opening the foil pouch. Put the test device on a clean and flat surface.
 - 3.2 twist open the small white cap from the extraction tube, transfer 3 drop of sample into the sample well of test device vertically.
 - 3.3 Read the result at 10~20 minutes. Don' t interpret the result after 20 minutes.

Note: The detection steps need to be completed under protection against infection.

VI. Statistical methods of statistical analysis of clinical research data

A Methods evaluating clinical performance

Whether various indexes can reach the standards of clinical evaluation shall be judged by calculating the consistency percentage of negative/positive and the total consistency percentage in the test results of the product tested and the reference product, to validate the accuracy and applicability of the product in clinical applications. The product tested shall be subject to tests through the sample of different types, with statistics on the results. Meanwhile, different types of sample of the subjects shall be subject to determination by the product tested synchronously, and then the determination results of both shall be compared. The test results recorded shall be subject to statistical analysis upon completion of determination of all clinical samples, to calculate the consistency percentage of negative/positive and the total consistency percentage. Afterwards, equivalence of both shall be evaluated as per these statistical indexes

B Statistical method

The products launched on the market shall be subject to comparative study and evaluation. Kappa inspection: each sample shall be tested with the product tested and the reference product respectively, and then the consistency in statistical results of these two inspection methods shall be compared through Kappa inspection.

The data shall be subject to Kappa inspection and analysis and the Kappa coefficient shall be calculated. Favorable consistency can be proven if Kappa is >0.8 . The consistency in test results

of the product tested and the reference product is evaluated as per the evaluation standards.

VII Standards of clinical evaluation

The coincidence rate shall be calculated by comparing with the reference product whose marketing is approved. The product performance shall meet the following requirements.

- 1) Coincidence rate of negative: the sample whose test results are negative for both the product tested and the reference product and the proportion in the sample whose test results are negative for the reference product shall be more than 95%.
- 2) Coincidence rate of positive: the sample whose test results are positive for both the product tested and the reference product and the proportion in the sample whose test results are positive for the reference product shall be more than 85%.
- 3) Total coincidence rate: the sample whose test results are the same for the product tested and the reference product and its proportion in the total number of samples shall be more than 90%.

Method		2019-nCoV nucleic acid test kit (RT-PCR)		Total Results
The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)	Result	positive	negative	
	positive	A	B	A+B
	negative	C	D	C+D
Total Results		A+C	B+D	A+B+C+D

Clinical sensitivity = $A/(A+C)*100\%$

Clinical specificity = $D/(B+D)*100\%$

Accuracy: $(A+D)/(A+B+C+D)*100\%$

If the coincidence rate of positive/negative can meet clinical requirements, two methods or Products are considered as equivalent; If the coincidence rate of positive/negative is greatly different, the clinical scheme should be re-designed.

- 4) Kappa consistency analysis shall be adopted for statistical analysis of reference reagents.

The results of the product tested are statistical materials and can be per the table below:

Method		2019-nCoV nucleic acid test kit (RT-PCR)		Total Results
The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)	Result	positive	negative	
	positive	A	B	A+B
	negative	C	D	C+D
Total Results		A+C	B+D	A+B+C+D

$P_0 = (A+D)/(A+B+C+D)*100\%$

$P_e = ((A+B)(A+C) + (A+B)(B+D)) / (A+B+C+D)^2$

Kappa: $(P_0 - P_e) / (1 - P_e)$

If conducting Kappa consistency analysis for the base data above, high consistency can be judged if the Kappa coefficient is >0.8 , and both systems are considered as equivalent. Consistency is

considered if $0.4 < \text{Kappa coefficient} < 0.8$, and the coincidence rate of positive/negative shall be compared, with statistical analysis being made. Two such systems are considered as inconsistent and in-equivalent if the Kappa coefficient is < 0.4 .

VIII Provisions for amendments to clinical validation

In general, the clinical validation should not be changed. Any modification to the project during the test should be explained, and the time, reason, process of change, and whether there is a record of the change are explained in detail and its impact on the evaluation of the entire research result is explained.

IX. Results and Analysis of Clinical Tests

In total, 222 patients' samples are included for the unit, all the saliva samples and nasopharyngeal swab samples are tested. Statistics on rapid test results and those of the RT-PCR tested are as follows:

Method		2019-nCoV Nucleic Acid Test Kit (RT-PCR)		Total Results
		Positive	Negative	
The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Cassette (Swab)	Results			
	Positive	62	0	62
	Negative	4	156	160
Total Results		66	156	222

Clinical sensitivity = $62/66 = 93.94\%$ (95%CI*84.99% to 98.06%)

Clinical specificity = $156/156 > 99.9\%$ (95%CI* 98.98% to 100%)

Accuracy: $(62+156)/(62+0+4+156) * 100\% = 98.20\%$ (95%CI* 95.29% to 99.46%)

$P_e = (62*66+62*156)/222*222 = 0.28$

Kappa: $(P_0 - P_e)/(1 - p_e) = 0.97$

*:95% confidence interval

According to the above table, 156 are proven negative of 156 negative specimens, 62 are proven positive of 66 positive specimens. The sensitivity and accuracy are more than 90%, indicating favorable consistency with the reference product. The Kappa=0.97>0.8, indicating favorable and high consistency of two methods and equivalence of two such systems.

X Analysis on Inconsistency in Test Results

NO.	Age	Gender	Rapid Test	RT-PCR	Clinical diagnostic
14	39	F	Negative	Positive (N gene)	Infection 25 days
25	43	F	Negative	Positive (N gene)	Infection 16 days
37	36	M	Negative	Positive (N gene)	Infection 28 days
49	30	M	Negative	Positive (RdRP gene)	Infection 22 days

XI Discussion and Conclusions

1. discussion

A Results of comparative analysis of the product tested and the reference product:

Test results of saliva specimen tested and the reference result: both the coincidence rate of negative/positive and the total coincidence rate are larger than 85%, indicating favorable consistency with the reference product. In the analysis results of Kappa inspection, Kappa was

proven >0.8 , indicating favorable and high consistency of both methods. Both systems were proven equivalent.

2. Test conclusions

By analyzing the test results of the product tested and the reference product, the consistency percentage of negative/positive and the total consistency percentage are proven high. Moreover, according to the results of statistical analysis, there is no remarkable difference in test results of both, indicating favorable consistency in diagnosis and equivalence of two such systems and can be used for auxiliary diagnosis of those suffering from pneumonia triggered by COVID-19.

X. Quality control methods

On-site quality control

1) During the course of this study, clinical implementors appointed clinical inspectors to conduct regular on-site supervision visits to the research hospital. Through monitoring visits, it was found that all the contents of the research plan were strictly observed, and the correctness of the research data was also guaranteed. Participating researchers have undergone unified training, unified recording methods and judgment standards. The entire clinical trial process is conducted under strict operation, and the test content is complete and authentic. All observations and findings in the clinical trials have been verified and the data are reliable. The conclusions in the clinical trials are derived from the original data.

2) Quality control of clinical experiment process

During the evaluation, quality control was performed daily to ensure that the product was under control. Strict quality control is performed for each trial to ensure the quality of clinical trials.

XI. Prediction of adverse events

Because the Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) is an in vitro diagnostic reagent product, no direct contact with patients is required in clinical trials, no test report is provided to patients, and the test results are only used for comparative studies. It involves personal privacy, does not serve as a basis for auxiliary diagnosis, does not bring any risk to the subject, and does not cause adverse events.

References:

1. The "Technical Review Points for the Registration of New Coronavirus Antigen / Antibody Detection Reagents in 2019 (Trial)" issued by the State Drug Administration Medical Device Technical Evaluation Center on February 25, 2020;
2. "Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 7)" issued by the National Health Committee on February 19, 2020.

Annex I : Package Insert

Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test device (saliva)

Package Insert

A RAPID TEST FOR THE QUALITATIVE DETECTION OF NOVEL CORONAVIRUS ANTIGENS IN HUMAN

For professional in vitro diagnostic use only.

INTENDED USE

The Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test device (saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid monoclonal antibody method. The detection limit is 100 copies/mL. It is not intended for use as a confirmatory test for the detection of novel coronavirus antigens. It will provide information for clinical doctors to prescribe correct medications.

SUMMARY

COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection. Asymptomatic infection can also be detected. The incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

PRINCIPLE

The Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test device (saliva) is an immunochromatographic membrane assay that uses highly sensitive monoclonal antibodies to detect novel coronavirus antigens. The test strip is composed of the following three parts: namely sample pad, reagent pad and reaction membrane. The reagent membrane contains the colloidal gold conjugated with the monoclonal antibodies against novel coronavirus. The reaction membrane contains the secondary antibodies for novel coronavirus, and the polyclonal antibodies against the mouse monoclonal antibodies for novel coronavirus. When the test device was inserted into saliva sample, conjugates dried in the reagent pad are dissolved and migrate along with the sample. If novel coronavirus is present in the sample, a complex formed along with the anti-novel coronavirus conjugate and the virus will be caught by the specific anti-novel coronavirus monoclonal antibodies in the reaction membrane. If not, another reagent (an anti-mouse IgG antibody) that binds the remaining conjugates, thereby producing a red line on the reaction C.

REAGENTS

The reagent membrane contains the colloidal gold conjugated with the monoclonal antibodies against novel coronavirus. The reaction membrane contains the secondary antibodies for novel coronavirus. The test device is pre-immobilized on the membrane.

PRECAUTIONS

- For in vitro diagnostic use only.
- Do not use after the expiration date.
- Ensure the pouch containing test device is not damaged before opening for use.
- Do not use the test device if the pouch is damaged or the test device is expired.
- Wear gloves when handling the samples, avoid touching the reagent membrane and sample window.
- All samples and used accessories should be treated as infectious and discarded according to local regulations.

STORAGE AND STABILITY

Store The Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test device (saliva) at room temperature or refrigerated (2-30°C). Do not freeze. All reagents are stable until the expiration date marked on their outer packaging and buffer vial.

SPECIMEN COLLECTION AND PREPARATION

1. Specimen collection: Specimens should be collected using the saliva collector provided with the kit. Follow the detailed Directions for Use below. No other collection cap should be used with this assay. Oral fluid collected at any time of the day may be used.

2. Specimen preparation: Specimen preparation: Remove the aluminum foil insert, the sponge of sample holder and the saliva collector into the tube and last close the whole cap of sample collector.

MATERIALS


- Test device
- Saliva collector
- Extraction Tube with extraction buffer
- Package Insert
- Tube Stand

Materials required but not provided

DIRECTIONS FOR USE

Allow the test device, specimen, extraction buffer to equilibrate to room temperature (15-30°C) prior to testing. Do not place anything in the mouth including food, drink, toothpaste and mouthwash products for at least 10 minutes prior to collection of oral fluid specimen.

- Open the package with the saliva collector, then remove the saliva collector from the sealed plastic bag.
- Insert the sponge of saliva collector into the mouth, actively swell the inside of the mouth and tongue to collect oral fluid for approximately 10 seconds until the sponge becomes soft and fully saturated.
- Take out a sample extraction tube, remove the aluminum foil. Remove the collector from the mouth and put the saturated oral fluid collector into the extraction tube.
- Screw the cap into the extraction tube tightly so that saliva is squeezed out of the sponge into the extraction tube.
- Remove the cap, the extraction tube vertically for about 5 seconds to allow saliva mix well with extraction buffer. Take out the saliva collector and discard it.
- Remove the test device from the sealed foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed immediately after opening the foil pouch. Put the test device on a clean and flat surface.
- Transfer the sample from the extraction tube transfer 3 drop of sample into the sample well of test device vertically.
- Read the result at 10-20 minutes. Don't interpret the result after 20 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

POSITIVE: Two red lines appear. One red line appears in the control region (C), and one red line appears in the test region (T). The shade of color may vary, but it should be considered positive whenever there is even a faint line.

NEGATIVE: Only one red line appears in the control region (C), and no line in the test region (T). This indicates that the sample is negative for novel coronavirus antigens.

INVALID: No red line appears in the control region (C). The test is invalid even if there is a line on the test region (T). Insufficient sample volume or incorrect procedural techniques are the most likely causes of this failure. Repeat the test using a new specimen and a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

LIMITATIONS

- The Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test device (saliva) is an acute-phase screening test for qualitative detection. Sample collected may contain antigen concentration below the reagent's sensitivity threshold, so a negative test result does not include infection with novel coronavirus.
- The Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test device (saliva) detects visible and non-visible novel coronavirus antigen. Test performance depends on antigen load in the sample and may not correlate with cell culture performed on the same sample. A positive test does not indicate the severity of the infection. The test result should be interpreted in conjunction with all other available clinical and laboratory information to make an accurate diagnosis.
- A negative test result may occur if the level of antigen in a specimen is below the sensitivity of the test or if poor quality specimen is obtained.
- Results of the test have not been established for monitoring antiviral treatment of novel coronavirus.
- Positive test results do not rule out co-infections with other pathogens.
- Negative test results are not intended to rule in other coronavirus infection except the SARS-CoV-2.
- NOVEL 1, NOVEL 2, NOVEL 3, NOVEL 4, NOVEL 5, NOVEL 6, NOVEL 7, NOVEL 8, NOVEL 9, NOVEL 10, NOVEL 11, NOVEL 12, NOVEL 13, NOVEL 14, NOVEL 15, NOVEL 16, NOVEL 17, NOVEL 18, NOVEL 19, NOVEL 20, NOVEL 21, NOVEL 22, NOVEL 23, NOVEL 24, NOVEL 25, NOVEL 26, NOVEL 27, NOVEL 28, NOVEL 29, NOVEL 30, NOVEL 31, NOVEL 32, NOVEL 33, NOVEL 34, NOVEL 35, NOVEL 36, NOVEL 37, NOVEL 38, NOVEL 39, NOVEL 40, NOVEL 41, NOVEL 42, NOVEL 43, NOVEL 44, NOVEL 45, NOVEL 46, NOVEL 47, NOVEL 48, NOVEL 49, NOVEL 50, NOVEL 51, NOVEL 52, NOVEL 53, NOVEL 54, NOVEL 55, NOVEL 56, NOVEL 57, NOVEL 58, NOVEL 59, NOVEL 60, NOVEL 61, NOVEL 62, NOVEL 63, NOVEL 64, NOVEL 65, NOVEL 66, NOVEL 67, NOVEL 68, NOVEL 69, NOVEL 70, NOVEL 71, NOVEL 72, NOVEL 73, NOVEL 74, NOVEL 75, NOVEL 76, NOVEL 77, NOVEL 78, NOVEL 79, NOVEL 80, NOVEL 81, NOVEL 82, NOVEL 83, NOVEL 84, NOVEL 85, NOVEL 86, NOVEL 87, NOVEL 88, NOVEL 89, NOVEL 90, NOVEL 91, NOVEL 92, NOVEL 93, NOVEL 94, NOVEL 95, NOVEL 96, NOVEL 97, NOVEL 98, NOVEL 99, NOVEL 100, NOVEL 101, NOVEL 102, NOVEL 103, NOVEL 104, NOVEL 105, NOVEL 106, NOVEL 107, NOVEL 108, NOVEL 109, NOVEL 110, NOVEL 111, NOVEL 112, NOVEL 113, NOVEL 114, NOVEL 115, NOVEL 116, NOVEL 117, NOVEL 118, NOVEL 119, NOVEL 120, NOVEL 121, NOVEL 122, NOVEL 123, NOVEL 124, NOVEL 125, NOVEL 126, NOVEL 127, NOVEL 128, NOVEL 129, NOVEL 130, NOVEL 131, NOVEL 132, NOVEL 133, NOVEL 134, NOVEL 135, NOVEL 136, NOVEL 137, NOVEL 138, NOVEL 139, NOVEL 140, NOVEL 141, NOVEL 142, NOVEL 143, NOVEL 144, NOVEL 145, NOVEL 146, NOVEL 147, NOVEL 148, NOVEL 149, NOVEL 150, NOVEL 151, NOVEL 152, NOVEL 153, NOVEL 154, NOVEL 155, NOVEL 156, NOVEL 157, NOVEL 158, NOVEL 159, NOVEL 160, NOVEL 161, NOVEL 162, NOVEL 163, NOVEL 164, NOVEL 165, NOVEL 166, NOVEL 167, NOVEL 168, NOVEL 169, NOVEL 170, NOVEL 171, NOVEL 172, NOVEL 173, NOVEL 174, NOVEL 175, NOVEL 176, NOVEL 177, NOVEL 178, NOVEL 179, NOVEL 180, NOVEL 181, NOVEL 182, NOVEL 183, NOVEL 184, NOVEL 185, NOVEL 186, NOVEL 187, NOVEL 188, NOVEL 189, NOVEL 190, NOVEL 191, NOVEL 192, NOVEL 193, NOVEL 194, NOVEL 195, NOVEL 196, NOVEL 197, NOVEL 198, NOVEL 199, NOVEL 200, NOVEL 201, NOVEL 202, NOVEL 203, NOVEL 204, NOVEL 205, NOVEL 206, NOVEL 207, NOVEL 208, NOVEL 209, NOVEL 210, NOVEL 211, NOVEL 212, NOVEL 213, NOVEL 214, NOVEL 215, NOVEL 216, NOVEL 217, NOVEL 218, NOVEL 219, NOVEL 220, NOVEL 221, NOVEL 222, NOVEL 223, NOVEL 224, NOVEL 225, NOVEL 226, NOVEL 227, NOVEL 228, NOVEL 229, NOVEL 230, NOVEL 231, NOVEL 232, NOVEL 233, NOVEL 234, NOVEL 235, NOVEL 236, NOVEL 237, NOVEL 238, NOVEL 239, NOVEL 240, NOVEL 241, NOVEL 242, NOVEL 243, NOVEL 244, NOVEL 245, NOVEL 246, NOVEL 247, NOVEL 248, NOVEL 249, NOVEL 250, NOVEL 251, NOVEL 252, NOVEL 253, NOVEL 254, NOVEL 255, NOVEL 256, NOVEL 257, NOVEL 258, NOVEL 259, NOVEL 260, NOVEL 261, NOVEL 262, NOVEL 263, NOVEL 264, NOVEL 265, NOVEL 266, NOVEL 267, NOVEL 268, NOVEL 269, NOVEL 270, NOVEL 271, NOVEL 272, NOVEL 273, NOVEL 274, NOVEL 275, NOVEL 276, NOVEL 277, NOVEL 278, NOVEL 279, NOVEL 280, NOVEL 281, NOVEL 282, NOVEL 283, NOVEL 284, NOVEL 285, NOVEL 286, NOVEL 287, NOVEL 288, NOVEL 289, NOVEL 290, NOVEL 291, NOVEL 292, NOVEL 293, NOVEL 294, NOVEL 295, NOVEL 296, NOVEL 297, NOVEL 298, NOVEL 299, NOVEL 300, NOVEL 301, NOVEL 302, NOVEL 303, NOVEL 304, NOVEL 305, NOVEL 306, NOVEL 307, NOVEL 308, NOVEL 309, NOVEL 310, NOVEL 311, NOVEL 312, NOVEL 313, NOVEL 314, NOVEL 315, NOVEL 316, NOVEL 317, NOVEL 318, NOVEL 319, NOVEL 320, NOVEL 321, NOVEL 322, NOVEL 323, NOVEL 324, NOVEL 325, NOVEL 326, NOVEL 327, NOVEL 328, NOVEL 329, NOVEL 330, NOVEL 331, NOVEL 332, NOVEL 333, NOVEL 334, NOVEL 335, NOVEL 336, NOVEL 337, NOVEL 338, NOVEL 339, NOVEL 340, NOVEL 341, NOVEL 342, NOVEL 343, NOVEL 344, NOVEL 345, NOVEL 346, NOVEL 347, NOVEL 348, NOVEL 349, NOVEL 350, NOVEL 351, NOVEL 352, NOVEL 353, NOVEL 354, NOVEL 355, NOVEL 356, NOVEL 357, NOVEL 358, NOVEL 359, NOVEL 360, NOVEL 361, NOVEL 362, NOVEL 363, NOVEL 364, NOVEL 365, NOVEL 366, NOVEL 367, NOVEL 368, NOVEL 369, NOVEL 370, NOVEL 371, NOVEL 372, NOVEL 373, NOVEL 374, NOVEL 375, NOVEL 376, NOVEL 377, NOVEL 378, NOVEL 379, NOVEL 380, NOVEL 381, NOVEL 382, NOVEL 383, NOVEL 384, NOVEL 385, NOVEL 386, NOVEL 387, NOVEL 388, NOVEL 389, NOVEL 390, NOVEL 391, NOVEL 392, NOVEL 393, NOVEL 394, NOVEL 395, NOVEL 396, NOVEL 397, NOVEL 398, NOVEL 399, NOVEL 400, NOVEL 401, NOVEL 402, NOVEL 403, NOVEL 404, NOVEL 405, NOVEL 406, NOVEL 407, NOVEL 408, NOVEL 409, NOVEL 410, NOVEL 411, NOVEL 412, NOVEL 413, NOVEL 414, NOVEL 415, NOVEL 416, NOVEL 417, NOVEL 418, NOVEL 419, NOVEL 420, NOVEL 421, NOVEL 422, NOVEL 423, NOVEL 424, NOVEL 425, NOVEL 426, NOVEL 427, NOVEL 428, NOVEL 429, NOVEL 430, NOVEL 431, NOVEL 432, NOVEL 433, NOVEL 434, NOVEL 435, NOVEL 436, NOVEL 437, NOVEL 438, NOVEL 439, NOVEL 440, NOVEL 441, NOVEL 442, NOVEL 443, NOVEL 444, NOVEL 445, NOVEL 446, NOVEL 447, NOVEL 448, NOVEL 449, NOVEL 450, NOVEL 451, NOVEL 452, NOVEL 453, NOVEL 454, NOVEL 455, NOVEL 456, NOVEL 457, NOVEL 458, NOVEL 459, NOVEL 460, NOVEL 461, NOVEL 462, NOVEL 463, NOVEL 464, NOVEL 465, NOVEL 466, NOVEL 467, NOVEL 468, NOVEL 469, NOVEL 470, NOVEL 471, NOVEL 472, NOVEL 473, NOVEL 474, NOVEL 475, NOVEL 476, NOVEL 477, NOVEL 478, NOVEL 479, NOVEL 480, NOVEL 481, NOVEL 482, NOVEL 483, NOVEL 484, NOVEL 485, NOVEL 486, NOVEL 487, NOVEL 488, NOVEL 489, NOVEL 490, NOVEL 491, NOVEL 492, NOVEL 493, NOVEL 494, NOVEL 495, NOVEL 496, NOVEL 497, NOVEL 498, NOVEL 499, NOVEL 500, NOVEL 501, NOVEL 502, NOVEL 503, NOVEL 504, NOVEL 505, NOVEL 506, NOVEL 507, NOVEL 508, NOVEL 509, NOVEL 510, NOVEL 511, NOVEL 512, NOVEL 513, NOVEL 514, NOVEL 515, NOVEL 516, NOVEL 517, NOVEL 518, NOVEL 519, NOVEL 520, NOVEL 521, NOVEL 522, NOVEL 523, NOVEL 524, NOVEL 525, NOVEL 526, NOVEL 527, NOVEL 528, NOVEL 529, NOVEL 530, NOVEL 531, NOVEL 532, NOVEL 533, NOVEL 534, NOVEL 535, NOVEL 536, NOVEL 537, NOVEL 538, NOVEL 539, NOVEL 540, NOVEL 541, NOVEL 542, NOVEL 543, NOVEL 544, NOVEL 545, NOVEL 546, NOVEL 547, NOVEL 548, NOVEL 549, NOVEL 550, NOVEL 551, NOVEL 552, NOVEL 553, NOVEL 554, NOVEL 555, NOVEL 556, NOVEL 557, NOVEL 558, NOVEL 559, NOVEL 560, NOVEL 561, NOVEL 562, NOVEL 563, NOVEL 564, NOVEL 565, NOVEL 566, NOVEL 567, NOVEL 568, NOVEL 569, NOVEL 570, NOVEL 571, NOVEL 572, NOVEL 573, NOVEL 574, NOVEL 575, NOVEL 576, NOVEL 577, NOVEL 578, NOVEL 579, NOVEL 580, NOVEL 581, NOVEL 582, NOVEL 583, NOVEL 584, NOVEL 585, NOVEL 586, NOVEL 587, NOVEL 588, NOVEL 589, NOVEL 590, NOVEL 591, NOVEL 592, NOVEL 593, NOVEL 594, NOVEL 595, NOVEL 596, NOVEL 597, NOVEL 598, NOVEL 599, NOVEL 600, NOVEL 601, NOVEL 602, NOVEL 603, NOVEL 604, NOVEL 605, NOVEL 606, NOVEL 607, NOVEL 608, NOVEL 609, NOVEL 610, NOVEL 611, NOVEL 612, NOVEL 613, NOVEL 614, NOVEL 615, NOVEL 616, NOVEL 617, NOVEL 618, NOVEL 619, NOVEL 620, NOVEL 621, NOVEL 622, NOVEL 623, NOVEL 624, NOVEL 625, NOVEL 626, NOVEL 627, NOVEL 628, NOVEL 629, NOVEL 630, NOVEL 631, NOVEL 632, NOVEL 633, NOVEL 634, NOVEL 635, NOVEL 636, NOVEL 637, NOVEL 638, NOVEL 639, NOVEL 640, NOVEL 641, NOVEL 642, NOVEL 643, NOVEL 644, NOVEL 645, NOVEL 646, NOVEL 647, NOVEL 648, NOVEL 649, NOVEL 650, NOVEL 651, NOVEL 652, NOVEL 653, NOVEL 654, NOVEL 655, NOVEL 656, NOVEL 657, NOVEL 658, NOVEL 659, NOVEL 660, NOVEL 661, NOVEL 662, NOVEL 663, NOVEL 664, NOVEL 665, NOVEL 666, NOVEL 667, NOVEL 668, NOVEL 669, NOVEL 670, NOVEL 671, NOVEL 672, NOVEL 673, NOVEL 674, NOVEL 675, NOVEL 676, NOVEL 677, NOVEL 678, NOVEL 679, NOVEL 680, NOVEL 681, NOVEL 682, NOVEL 683, NOVEL 684, NOVEL 685, NOVEL 686, NOVEL 687, NOVEL 688, NOVEL 689, NOVEL 690, NOVEL 691, NOVEL 692, NOVEL 693, NOVEL 694, NOVEL 695, NOVEL 696, NOVEL 697, NOVEL 698, NOVEL 699, NOVEL 700, NOVEL 701, NOVEL 702, NOVEL 703, NOVEL 704, NOVEL 705, NOVEL 706, NOVEL 707, NOVEL 708, NOVEL 709, NOVEL 710, NOVEL 711, NOVEL 712, NOVEL 713, NOVEL 714, NOVEL 715, NOVEL 716, NOVEL 717, NOVEL 718, NOVEL 719, NOVEL 720, NOVEL 721, NOVEL 722, NOVEL 723, NOVEL 724, NOVEL 725, NOVEL 726, NOVEL 727, NOVEL 728, NOVEL 729, NOVEL 730, NOVEL 731, NOVEL 732, NOVEL 733, NOVEL 734, NOVEL 735, NOVEL 736, NOVEL 737, NOVEL 738, NOVEL 739, NOVEL 740, NOVEL 741, NOVEL 742, NOVEL 743, NOVEL 744, NOVEL 745, NOVEL 746, NOVEL 747, NOVEL 748, NOVEL 749, NOVEL 750, NOVEL 751, NOVEL 752, NOVEL 753, NOVEL 754, NOVEL 755, NOVEL 756, NOVEL 757, NOVEL 758, NOVEL 759, NOVEL 760, NOVEL 761, NOVEL 762, NOVEL 763, NOVEL 764, NOVEL 765, NOVEL 766, NOVEL 767, NOVEL 768, NOVEL 769, NOVEL 770, NOVEL 771, NOVEL 772, NOVEL 773, NOVEL 774, NOVEL 775, NOVEL 776, NOVEL 777, NOVEL 778, NOVEL 779, NOVEL 780, NOVEL 781, NOVEL 782, NOVEL 783, NOVEL 784, NOVEL 785, NOVEL 786, NOVEL 787, NOVEL 788, NOVEL 789, NOVEL 790, NOVEL 791, NOVEL 792, NOVEL 793, NOVEL 794, NOVEL 795, NOVEL 796, NOVEL 797, NOVEL 798, NOVEL 799, NOVEL 800, NOVEL 801, NOVEL 802, NOVEL 803, NOVEL 804, NOVEL 805, NOVEL 806, NOVEL 807, NOVEL 808, NOVEL 809, NOVEL 810, NOVEL 811, NOVEL 812, NOVEL 813, NOVEL 814, NOVEL 815, NOVEL 816, NOVEL 817, NOVEL 818, NOVEL 819, NOVEL 820, NOVEL 821, NOVEL 822, NOVEL 823, NOVEL 824, NOVEL 825, NOVEL 826, NOVEL 827, NOVEL 828, NOVEL 829, NOVEL 830, NOVEL 831, NOVEL 832, NOVEL 833, NOVEL 834, NOVEL 835, NOVEL 836, NOVEL 837, NOVEL 838, NOVEL 839, NOVEL 840, NOVEL 841, NOVEL 842, NOVEL 843, NOVEL 844, NOVEL 845, NOVEL 846, NOVEL 847, NOVEL 848, NOVEL 849, NOVEL 850, NOVEL 851, NOVEL 852, NOVEL 853, NOVEL 854, NOVEL 855, NOVEL 856, NOVEL 857, NOVEL 858, NOVEL 859, NOVEL 860, NOVEL 861, NOVEL 862, NOVEL 863, NOVEL 864, NOVEL 865, NOVEL 866, NOVEL 867, NOVEL 868, NOVEL 869, NOVEL 870, NOVEL 871, NOVEL 872, NOVEL 873, NOVEL 874, NOVEL 875, NOVEL 876, NOVEL 877, NOVEL 878, NOVEL 879, NOVEL 880, NOVEL 881, NOVEL 882, NOVEL 883, NOVEL 884, NOVEL 885, NOVEL 886, NOVEL 887, NOVEL 888, NOVEL 889, NOVEL 890, NOVEL 891, NOVEL 892, NOVEL 893, NOVEL 894, NOVEL 895, NOVEL 896, NOVEL 897, NOVEL 898, NOVEL 899, NOVEL 900, NOVEL 901, NOVEL 902, NOVEL 903, NOVEL 904, NOVEL 905, NOVEL 906, NOVEL 907, NOVEL 908, NOVEL 909, NOVEL 910, NOVEL 911, NOVEL 912, NOVEL 913, NOVEL 914, NOVEL 915, NOVEL 916, NOVEL 917, NOVEL 918, NOVEL 919, NOVEL 920, NOVEL 921, NOVEL 922, NOVEL 923, NOVEL 924, NOVEL 925, NOVEL 926, NOVEL 927, NOVEL 928, NOVEL 929, NOVEL 930, NOVEL 931, NOVEL 932, NOVEL 933, NOVEL 934, NOVEL 935, NOVEL 936, NOVEL 937, NOVEL 938, NOVEL 939, NOVEL 940, NOVEL 941, NOVEL 942, NOVEL 943, NOVEL 944, NOVEL 945, NOVEL 946, NOVEL 947, NOVEL 948, NOVEL 949, NOVEL 950, NOVEL 951, NOVEL 952, NOVEL 953, NOVEL 954, NOVEL 955, NOVEL 956, NOVEL 957, NOVEL 958, NOVEL 959, NOVEL 960, NOVEL 961, NOVEL 962, NOVEL 963, NOVEL 964, NOVEL 965, NOVEL 966, NOVEL 967, NOVEL 968, NOVEL 969, NOVEL 970, NOVEL 971, NOVEL 972, NOVEL 973, NOVEL 974, NOVEL 975, NOVEL 976, NOVEL 977, NOVEL 978, NOVEL 979, NOVEL 980, NOVEL 981, NOVEL 982, NOVEL 983, NOVEL 984, NOVEL 985, NOVEL 986, NOVEL 987, NOVEL 988, NOVEL 989, NOVEL 990, NOVEL 991, NOVEL 992, NOVEL 993, NOVEL 994, NOVEL 995, NOVEL 996, NOVEL 997, NOVEL 998, NOVEL 999, NOVEL 1000, NOVEL 1001, NOVEL 1002, NOVEL 1003, NOVEL 1004, NOVEL 1005, NOVEL 1006, NOVEL 1007, NOVEL 1008, NOVEL 1009, NOVEL 1010, NOVEL 1011, NOVEL 1012, NOVEL 1013, NOVEL 1014, NOVEL 1015, NOVEL 1016, NOVEL 1017, NOVEL 1018, NOVEL 1019, NOVEL 1020, NOVEL 1021, NOVEL 1022, NOVEL 1023, NOVEL 1024, NOVEL 1025, NOVEL 1026, NOVEL 1027, NOVEL 1028, NOVEL 1029, NOVEL 1030, NOVEL 1031, NOVEL 1032, NOVEL 1033, NOVEL 1034, NOVEL 1035, NOVEL 1036, NOVEL 1037, NOVEL 1038, NOVEL 1039, NOVEL 1040, NOVEL 1041, NOVEL 1042, NOVEL 1043, NOVEL 1044, NOVEL 1045, NOVEL 1046, NOVEL 1047, NOVEL 1048, NOVEL 1049, NOVEL 1050, NOVEL 1051, NOVEL 1052, NOVEL 1053, NOVEL 1054, NOVEL 1055, NOVEL 1056, NOVEL 1057, NOVEL 1058, NOVEL 1059, NOVEL 1060, NOVEL 1061, NOVEL 1062, NOVEL 1063, NOVEL 1064, NOVEL 1065, NOVEL 1066, NOVEL 1067, NOVEL 1068, NOVEL 1069, NOVEL 1070, NOVEL 1071, NOVEL 1072, NOVEL 1073, NOVEL 1074, NOVEL 1075, NOVEL 1076, NOVEL 1077, NOVEL 1078, NOVEL 1079, NOVEL 1080, NOVEL 1081, NOVEL 1082, NOVEL 1083, NOVEL 1084, NOVEL 1085, NOVEL 1086, NOVEL 1087, NOVEL 1088, NOVEL 1089, NOVEL 1090, NOVEL 1091, NOVEL 1092, NOVEL 1093, NOVEL 1094, NOVEL 1095, NOVEL 1096, NOVEL 1097, NOVEL 1098, NOVEL 1099, NOVEL 1100, NOVEL 1101, NOVEL 1102, NOVEL 1103, NOVEL 1104, NOVEL 1105, NOVEL 1106, NOVEL 1107, NOVEL 1108, NOVEL 1109, NOVEL 1110, NOVEL 1111, NOVEL 1112, NOVEL 1113, NOVEL 1114, NOVEL 1115, NOVEL 1116, NOVEL 1117, NOVEL 1118, NOVEL 1119, NOVEL 1120, NOVEL 1121, NOVEL 1122, NOVEL 1123, NOVEL 1124, NOVEL 1125, NOVEL 1126, NOVEL 1127, NOVEL 1128, NOVEL 1129, NOVEL 1130, NOVEL 1131, NOVEL 1132, NOVEL 1133, NOVEL 1134, NOVEL 1135, NOVEL 1136, NOVEL 1137, NOVEL 1138, NOVEL 1139, NOVEL 1140, NOVEL 1141, NOVEL 1142, NOVEL 1143, NOVEL 1144, NOVEL 1145, NOVEL 1146, NOVEL 1147, NOVEL 1148, NOVEL 1149, NOVEL 1150, NOVEL 1151, NOVEL 1152, NOVEL 1153, NOVEL 1154, NOVEL 1155, NOVEL 1156, NOVEL 1157, NOVEL 1158, NOVEL 1159, NOVEL 1160, NOVEL 1161, NOVEL 1162, NOVEL 1163, NOVEL 1164, NOVEL 1165, NOVEL 1166, NOVEL 1167, NOVEL 1168, NOVEL 1169, NOVEL 1170, NOVEL 1171, NOVEL 1172, NOVEL 1173, NOVEL 1174, NOVEL 1175, NOVEL 1176, NOVEL 1177, NOVEL 1178, NOVEL 1179, NOVEL 1180, NOVEL 1181, NOVEL 1182, NOVEL 1183, NOVEL 1184, NOVEL 1185, NOVEL 1186, NOVEL 1187, NOVEL 1188, NOVEL 1189, NOVEL 1190, NOVEL 1191, NOVEL 1192, NOVEL 1193, NOVEL 1194, NOVEL 1195, NOVEL 1196, NOVEL 1197, NOVEL 1198, NOVEL 1199, NOVEL 1200, NOVEL 1201, NOVEL 1202, NOVEL 1203, NOVEL 1204, NOVEL 1205, NOVEL 1206, NOVEL 1207, NOVEL 1208, NOVEL 1209, NOVEL 1210, NOVEL 1211, NOVEL 1212, NOVEL 1213, NOVEL 1214, NOVEL 1215, NOVEL 1216, NOVEL 1217, NOVEL 1218, NOVEL 1219, NOVEL 1220, NOVEL 1221, NOVEL 1222, NOVEL 1223, NOVEL 1224, NOVEL 1225, NOVEL 1226, NOVEL 1227, NOVEL 1228, NOVEL 1229, NOVEL 1230, NOVEL 1231, NOVEL 1232, NOVEL 1233, NOVEL 1234, NOVEL 1235, NOVEL 1236, NOVEL 1237, NOVEL 1238, NOVEL 1239, NOVEL 1240, NOVEL 1241, NOVEL 1242, NOVEL 1243, NOVEL 1244, NOVEL 1245, NOVEL 1246, NOVEL 1247, NOVEL 1248, NOVEL 1249, NOVEL 1250, NOVEL 1251, NOVEL 1252, NOVEL 1253, NOVEL 1254, NOVEL 1255, NOVEL 1256, NOVEL 1257, NOVEL 1258, NOVEL 1259, NOVEL 1260, NOVEL 1261, NOVEL 1262, NOVEL 1263, NOVEL 1264, NOVEL 1265, NOVEL 1266, NOVEL 1267, NOVEL 1268, NOVEL 1269, NOVEL 1270, NOVEL 1271, NOVEL 1272, NOVEL 1273, NOVEL 1274, NOVEL 1275, NOVEL 1276, NOVEL 1277, NOVEL 1278, NOVEL 1279, NOVEL 1280, NOVEL 1281, NOVEL 1282, NOVEL 1283, NOVEL 1284, NOVEL 1285, NOVEL 1286, NOVEL 1287, NOVEL 1288, NOVEL 1289, NOVEL 1290, NOVEL 1291, NOVEL 1292, NOVEL 1293, NOVEL 1294, NOVEL 1295, NOVEL 1296, NOVEL 1297, NOVEL 12

Human rhinovirus (HRV) 3 Type B	Penicillin	1.5 x 10 ⁷ TCID ₅₀ /ml
Human rhinovirus (HRV) 16 Type A1	IA10-2003	1.5 x 10 ⁷ TCID ₅₀ /ml
Parainfluenza virus	Type 1	1.5 x 10 ⁶ TCID ₅₀ /ml
	Type 2	1.5 x 10 ⁶ TCID ₅₀ /ml
	Type 3	1.5 x 10 ⁶ TCID ₅₀ /ml
	Type 4A	1.5 x 10 ⁶ TCID ₅₀ /ml

Interfering Substances Reaction
When tested using the Nasal Spray, Rapid Test Cassette (web), there was no interference between the device reagents and the potential interference substances listed in below table that would create false positive or negative results for SARS-CoV-2 antigen.

Substance	Concentration	Substance	Concentration
Human Blood	100µg/mL	Ascorbic acid	10mg/mL
Bilirubin	50mg/dL	Macrolide	2.5 mg/mL
Neo-Synephrine (Phenylephrine)	100µg/mL	Macrolide	10 mg/mL
Neo-Synephrine (Phenylephrine)	5% (w/v)	Erythromycin	10µg/mL
Alrin Nasal Spray (Oxymetazoline)	5% (w/v)	Erythromycin	50µg/mL
Saline Nasal Spray	5% (w/v)	Cefprozil	50µg/mL
Humectant	5% (w/v)	Cefprozil	10mg/mL
Sodium Cromoglycate	10 mg/mL	Chlorpheniramine	100µg/mL
Chlorpheniramine Hydrochloride	10 mg/mL	Chlorpheniramine	100µg/mL
Zinc Oxide	5 mg/mL	Hydrocortisone	100µg/mL
Oxalamin	10 mg/mL	Paracetamol	100µg/mL
Artether-lundantina	50µg/mL	Fluocortide	100µg/mL
Doxycycline hydrochloride	50µg/mL	Budesonide	5 µg/mL
Quinine	150µg/mL	Budesonide	5 µg/mL
Amoxicillin	1 mg/mL	Synovir	5 µg/mL
Acetaminophen	1 mg/mL	Synovir	5 µg/mL
		Alcohol	41.7 mg/mL
		Pooled human nasal wash	N/A

Symbol	Meaning	Symbol	Meaning
	In vitro diagnostic medical device		Storage temperature limit
	Manufacturer		Authorized representative in the European Community
	Date of Manufacture		Use by date
	Do not reuse		Consult instruction for use
	Lot		Meet the requirements of EC Directive 90/269/EEC

HANGZHOU REALY TECH CO., LTD.
4th Floor, #12 Building, Eastern Medicine Town,
Xiaoshan Economic & Technology Development,
310018 Hangzhou, Zhejiang, P. R. China
Website: www.realytech.com

Luxus Lebenswelt GmbH
Kodstr. 1, 47877, Willich, Germany

Number: 1101441891
Version: 1.0
Effective Date: 2020-11-13



Annex II: Data of Clinical Tests

NO.	Age	Gender	Rapid Test	(RT-PCR)
1	49	F	Positive	Positive (RdRP and N gene)
2	32	F	Positive	Positive (RdRP and N gene)
3	31	F	Positive	Positive (RdRP and N gene)
4	32	F	Positive	Positive (RdRP and N gene)
5	21	F	Positive	Positive (RdRP and N gene)
6	51	M	Positive	Positive (RdRP and N gene)
7	22	F	Positive	Positive (RdRP and N gene)
8	46	F	Positive	Positive (RdRP and N gene)
9	23	F	Positive	Positive (RdRP and N gene)
10	14	M	positive	Positive (RdRP and N gene)
11	42	M	Positive	Positive (RdRP and N gene)
12	51	M	Positive	Positive (RdRP and N gene)
13	80	M	Positive	Positive (RdRP and N gene)
14	39	F	Negative	Positive (N gene)
15	67	M	Positive	Positive (RdRP and N gene)
16	44	M	positive	Positive (RdRP gene)
17	26	F	Positive	Positive (RdRP and N gene)
18	33	F	positive	Positive (N gene)
19	38	F	Positive	Positive (RdRP and N gene)
20	36	F	Positive	Positive (RdRP and N gene)
21	3	F	Positive	Positive (RdRP and N gene)
22	35	F	Positive	Positive (RdRP and N gene)

NO.	Age	Gender	Rapid Test	(RT-PCR)
23	23	F	Positive	Positive (RdRP and N gene)
24	43	M	Positive	Positive (RdRP and N gene)
25	43	F	Negative	Positive (N gene)
26	46	F	Positive	Positive (RdRP and N gene)
27	55	F	Positive	Positive (RdRP and N gene)
28	22	F	Positive	Positive (RdRP and N gene)
29	20	M	positive	Positive (N gene)
30	42	M	Positive	Positive (RdRP and N gene)
31	56	F	Positive	Positive (RdRP and N gene)
32	55	M	Positive	Positive (RdRP and N gene)
33	26	F	Positive	Positive (RdRP and N gene)
34	54	M	Positive	Positive (RdRP and N gene)
35	43	F	Positive	Positive (RdRP and N gene)
36	69	M	Positive	Positive (RdRP and N gene)
37	36	M	Negative	Positive (N gene)
38	37	F	Positive	Positive (RdRP and N gene)
39	44	F	Positive	Positive (RdRP and N gene)
40	43	F	Positive	Positive (RdRP and N gene)
41	67	F	Positive	Positive (RdRP and N gene)
42	51	F	Positive	Positive (RdRP and N gene)
43	75	F	Positive	Positive (RdRP and N gene)
44	60	F	Positive	Positive (RdRP and N gene)

NO.	Age	Gender	Rapid Test	(RT-PCR)
45	25	M	Positive	Positive (RdRP and N gene)
46	75	F	Positive	Positive (RdRP and N gene)
47	43	F	Positive	Positive (RdRP and N gene)
48	30	F	Positive	Positive (RdRP and N gene)
49	30	M	Negative	Positive (RdRP gene)
50	26	F	Positive	Positive (RdRP and N gene)
51	32	F	Positive	Positive (RdRP and N gene)
52	73	M	Positive	Positive (RdRP and N gene)
53	58	F	Positive	Positive (RdRP and N gene)
54	66	F	Positive	Positive (RdRP and N gene)
55	29	F	Positive	Positive (RdRP and N gene)
56	56	M	Positive	Positive (RdRP and N gene)
57	24	M	Positive	Positive (N gene)
58	36	M	Positive	Positive (RdRP and N gene)
59	70	F	Positive	Positive (RdRP and N gene)
60	45	M	Positive	Positive (RdRP and N gene)
61	38	F	Positive	Positive (RdRP and N gene)
62	42	M	Positive	Positive (RdRP and N gene)
63	55	M	Positive	Positive (RdRP and N gene)
64	33	M	Positive	Positive (RdRP and N gene)
65	39	M	Positive	Positive (RdRP and N gene)
66	58	F	Positive	Positive (N gene)
67	77	F	Negative	Negative (Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
68	62	F	Negative	Negative (Ct/Cq) >40
69	81	M	Negative	Negative (Ct/Cq) >40
70	18	F	Negative	Negative (Ct/Cq) >40
71	71	F	Negative	Negative (Ct/Cq) >40
72	37	M	Negative	Negative (Ct/Cq) >40
73	44	F	Negative	Negative (Ct/Cq) >40
74	79	M	Negative	Negative (Ct/Cq) >40
75	67	M	Negative	Negative (Ct/Cq) >40
76	61	F	Negative	Negative (Ct/Cq) >40
77	59	F	Negative	Negative (Ct/Cq) >40
78	28	F	Negative	Negative (Ct/Cq) >40
79	82	M	Negative	Negative (Ct/Cq) >40
80	63	F	Negative	Negative (Ct/Cq) >40
81	53	M	Negative	Negative (Ct/Cq) >40
82	43	M	Negative	Negative (Ct/Cq) >40
83	46	M	Negative	Negative (Ct/Cq) >40
84	46	F	Negative	Negative (Ct/Cq) >40
85	21	F	Negative	Negative (Ct/Cq) >40
86	46	F	Negative	Negative (Ct/Cq) >40
87	71	M	Negative	Negative (Ct/Cq) >40
88	60	F	Negative	Negative (Ct/Cq) >40
89	31	F	Negative	Negative (Ct/Cq) >40
90	72	M	Negative	Negative (Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
91	62	M	Negative	Negative(Ct/Cq) >40
92	39	F	Negative	Negative(Ct/Cq) >40
93	45	M	Negative	Negative(Ct/Cq) >40
94	21	M	Negative	Negative(Ct/Cq) >40
95	33	M	Negative	Negative(Ct/Cq) >40
96	83	M	Negative	Negative(Ct/Cq) >40
97	15	M	Negative	Negative(Ct/Cq) >40
98	59	M	Negative	Negative(Ct/Cq) >40
99	54	M	Negative	Negative(Ct/Cq) >40
100	84	F	Negative	Negative(Ct/Cq) >40
101	84	F	Negative	Negative(Ct/Cq) >40
102	42	F	Negative	Negative(Ct/Cq) >40
103	63	F	Negative	Negative(Ct/Cq) >40
104	29	M	Negative	Negative(Ct/Cq) >40
105	50	M	Negative	Negative(Ct/Cq) >40
106	74	F	Negative	Negative(Ct/Cq) >40
107	43	M	Negative	Negative(Ct/Cq) >40
108	68	M	Negative	Negative(Ct/Cq) >40
109	29	M	Negative	Negative(Ct/Cq) >40
110	54	M	Negative	Negative(Ct/Cq) >40
111	49	M	Negative	Negative(Ct/Cq) >40
112	20	M	Negative	Negative(Ct/Cq) >40
113	26	M	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
114	22	M	Negative	Negative(Ct/Cq) >40
115	32	F	Negative	Negative(Ct/Cq) >40
116	28	M	Negative	Negative(Ct/Cq) >40
117	44	M	Negative	Negative(Ct/Cq) >40
118	57	F	Negative	Negative(Ct/Cq) >40
119	64	F	Negative	Negative(Ct/Cq) >40
120	39	F	Negative	Negative(Ct/Cq) >40
121	38	F	Negative	Negative(Ct/Cq) >40
122	73	M	Negative	Negative(Ct/Cq) >40
123	45	M	Negative	Negative(Ct/Cq) >40
124	61	M	Negative	Negative(Ct/Cq) >40
125	13	F	Negative	Negative(Ct/Cq) >40
126	64	F	Negative	Negative(Ct/Cq) >40
127	26	F	Negative	Negative(Ct/Cq) >40
128	28	M	Negative	Negative(Ct/Cq) >40
129	58	M	Negative	Negative(Ct/Cq) >40
130	35	F	Negative	Negative(Ct/Cq) >40
131	51	M	Negative	Negative(Ct/Cq) >40
132	60	M	Negative	Negative(Ct/Cq) >40
133	17	M	Negative	Negative(Ct/Cq) >40
134	18	F	Negative	Negative(Ct/Cq) >40
135	15	M	Negative	Negative(Ct/Cq) >40
136	52	M	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
137	33	M	Negative	Negative(Ct/Cq) >40
138	41	F	Negative	Negative(Ct/Cq) >40
139	11	M	Negative	Negative(Ct/Cq) >40
140	19	F	Negative	Negative(Ct/Cq) >40
141	10	F	Negative	Negative(Ct/Cq) >40
142	62	F	Negative	Negative(Ct/Cq) >40
143	68	F	Negative	Negative(Ct/Cq) >40
144	38	M	Negative	Negative(Ct/Cq) >40
145	59	M	Negative	Negative(Ct/Cq) >40
146	76	F	Negative	Negative(Ct/Cq) >40
147	24	M	Negative	Negative(Ct/Cq) >40
148	68	M	Negative	Negative(Ct/Cq) >40
149	82	F	Negative	Negative(Ct/Cq) >40
150	64	F	Negative	Negative(Ct/Cq) >40
151	59	M	Negative	Negative(Ct/Cq) >40
152	59	M	Negative	Negative(Ct/Cq) >40
153	83	M	Negative	Negative(Ct/Cq) >40
154	58	F	Negative	Negative(Ct/Cq) >40
155	68	M	Negative	Negative(Ct/Cq) >40
156	77	M	Negative	Negative(Ct/Cq) >40
157	47	F	Negative	Negative(Ct/Cq) >40
158	71	M	Negative	Negative(Ct/Cq) >40
159	21	F	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
160	52	M	Negative	Negative(Ct/Cq) >40
161	70	M	Negative	Negative(Ct/Cq) >40
162	63	M	Negative	Negative(Ct/Cq) >40
163	59	M	Negative	Negative(Ct/Cq) >40
164	26	M	Negative	Negative(Ct/Cq) >40
165	36	F	Negative	Negative(Ct/Cq) >40
166	47	F	Negative	Negative(Ct/Cq) >40
167	45	M	Negative	Negative(Ct/Cq) >40
168	29	F	Negative	Negative(Ct/Cq) >40
169	30	M	Negative	Negative(Ct/Cq) >40
170	25	F	Negative	Negative(Ct/Cq) >40
171	73	M	Negative	Negative(Ct/Cq) >40
172	76	M	Negative	Negative(Ct/Cq) >40
173	25	M	Negative	Negative(Ct/Cq) >40
174	49	F	Negative	Negative(Ct/Cq) >40
175	62	M	Negative	Negative(Ct/Cq) >40
176	38	M	Negative	Negative(Ct/Cq) >40
177	33	M	Negative	Negative(Ct/Cq) >40
178	39	M	Negative	Negative(Ct/Cq) >40
179	69	M	Negative	Negative(Ct/Cq) >40
180	79	F	Negative	Negative(Ct/Cq) >40
181	32	M	Negative	Negative(Ct/Cq) >40
182	35	M	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
183	39	M	Negative	Negative(Ct/Cq) >40
184	61	F	Negative	Negative(Ct/Cq) >40
185	10	F	Negative	Negative(Ct/Cq) >40
186	37	M	Negative	Negative(Ct/Cq) >40
187	52	F	Negative	Negative(Ct/Cq) >40
188	41	M	Negative	Negative(Ct/Cq) >40
189	74	M	Negative	Negative(Ct/Cq) >40
190	51	F	Negative	Negative(Ct/Cq) >40
191	56	M	Negative	Negative(Ct/Cq) >40
192	62	F	Negative	Negative(Ct/Cq) >40
193	60	F	Negative	Negative(Ct/Cq) >40
194	54	F	Negative	Negative(Ct/Cq) >40
195	81	F	Negative	Negative(Ct/Cq) >40
196	79	F	Negative	Negative(Ct/Cq) >40
197	73	F	Negative	Negative(Ct/Cq) >40
198	35	F	Negative	Negative(Ct/Cq) >40
199	76	F	Negative	Negative(Ct/Cq) >40
200	23	M	Negative	Negative(Ct/Cq) >40
201	13	F	Negative	Negative(Ct/Cq) >40
202	14	M	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
203	43	M	Negative	Negative(Ct/Cq) >40
204	30	F	Negative	Negative(Ct/Cq) >40
205	57	M	Negative	Negative(Ct/Cq) >40
206	30	F	Negative	Negative(Ct/Cq) >40
207	65	M	Negative	Negative(Ct/Cq) >40
208	66	F	Negative	Negative(Ct/Cq) >40
209	38	F	Negative	Negative(Ct/Cq) >40
210	49	M	Negative	Negative(Ct/Cq) >40
211	23	F	Negative	Negative(Ct/Cq) >40
212	51	M	Negative	Negative(Ct/Cq) >40
213	64	F	Negative	Negative(Ct/Cq) >40
214	67	M	Negative	Negative(Ct/Cq) >40
215	34	M	Negative	Negative(Ct/Cq) >40
216	55	M	Negative	Negative(Ct/Cq) >40
217	58	M	Negative	Negative(Ct/Cq) >40
218	67	F	Negative	Negative(Ct/Cq) >40
219	20	F	Negative	Negative(Ct/Cq) >40
220	42	M	Negative	Negative(Ct/Cq) >40
221	59	M	Negative	Negative(Ct/Cq) >40
222	12	M	Negative	Negative(Ct/Cq) >40

Director: 
Date: 2020.12.10
Seal of company signature

File No.:K590516D
Version:1.0
Effective date:2020-12-10